ferristene

oral magnetic particles composed of a ferrite-type crystalline iron oxide bound to a monodisperse nonbiodegradable organic polymer particles; not absorbed by the GI tract & does not cause systemic toxicity

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Wallengren, N O: 2 articles (11/2000 - 04/2000)
2.	Jonsson, E: 2 articles (04/2000 - 01/2000)
3.	Annweiler, A A: 1 article (11/2000)
4.	Judmaier, W: 1 article (11/2000)
5.	Kersting-Sommerhoff, B: 1 article (11/2000)
6.	Maier, A G: 1 article (11/2000)
7.	Meusel, M: 1 article (11/2000)
8.	Reeders, J W: 1 article (11/2000)
9.	Schima, W: 1 article (11/2000)
10.	Andrén-Sandberg, A: 1 article (04/2000)

Related Diseases

1.	Rectal Neoplasms (Rectal Cancer) 01/01/2000 - "The aim of this study was to compare three imaging strategies for the diagnosis of local recurrence of rectal cancer: (a) MR imaging; (b) MR imaging after administration of enteral superparamagnetic particles (Ferristene); and (c) contrast-enhanced CT. " 11/01/2000 - "The aim of this study was to assess the accuracy of double-contrast magnetic resonance imaging (MRI) with rectal application of the superparamagnetic iron oxide contrast agent (SPIO) ferristene and IV gadodiamide for preoperative staging of rectal cancer. " 11/01/2000 - "Staging of rectal cancer by double-contrast MR imaging using the rectally administered superparamagnetic iron oxide contrast agent ferristene and IV gadodiamide injection: results of a multicenter phase II trial."
2.	Neoplasms (Cancer) 11/01/2000 - "High-viscosity ferristene formulations were superior to low-viscosity formulations in tumor staging (accuracy 90% vs 74%, P < 0.01). " 04/01/2000 - "Double-contrast (ferristene solution plus gadodiamide) MR imaging was superior to imaging with only ferristene-based contrast material and had a sensitivity of 100%, specificity of 70%, and accuracy of 90% in distinguishing tumor stages worse than Dukes A. "
3.	Vomiting 07/01/1996 - "The incidence of adverse events was 9.0%, but only 3.6% of all patients experienced ferristene-related adverse events (e.g., nausea, vomiting). "
4.	Pancreatic Diseases (Pancreatic Disease) 07/01/1996 - "Ferristene increased the diagnostic information in 50.9% of the patients, particularly in those with abdominal masses, lymphoma, or pancreatic disease. "
5.	Nausea 07/01/1996 - "The incidence of adverse events was 9.0%, but only 3.6% of all patients experienced ferristene-related adverse events (e.g., nausea, vomiting). "

Related Drugs and Biologics

1.	Contrast Media
2.	gadodiamide (Omniscan)
3.	ferric oxide (iron oxide)
4.	Solutions

Related Therapies and Procedures

1.	Intravenous Injections
2.	Enema (Enemas)